Recon: Lilly’s Zepbound reduces obstructive sleep apnea in phase 3 trials; Sage abandons Parkinson's candidate after mid-stage study flop
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States